Neuropsychiatric manifestations of Systemic Lupus Erythematosus (NPSLE) are both common and an important source of morbidity. Of the case definitions for NPSLE syndromes that have recently been developed, cognitive dysfunction appears to be the most prevalent. A novel mechanism is that a subset of SLE patients with cognitive dysfunction have antibodies in the NR2 glutamate receptor. We propose, in a double -blind placebo-controlled trial, to dete...
more
Memantine in Systemic Lupus Erythematosus
Medical trial
ClinicalTrials.gov Identifier:
- NCT00181298
Type of trial:
Design:
View entire collection »Primary outcomes:
- Change in ANAM, Version 3.11
Start date:
- Mar 2006
End date:
- May 2007
Expected total enrollment:
- 61
Minimum age for eligibility:
- 18
Eligibility inclusion criteria:
- Self-reported cognitive impairment
- Clinical diagnosis of SLE
Eligibility exclusion criteria:
- Pregnancy
- Liver or renal insufficiency/failure (calculated creatinine clearance < 50 cc/min)
- Current alcohol or illicit drug abuse
- Current use of Namenda, Aricept, Provigil
- Severe SLE flare in the last 6 weeks (defined as SLEDAI > 12 points)
- History of non-compliance
- Recent (within 4 weeks) change in any medication relevant to cognitive function, including prednisone, anti-depressants, medications for insomnia, narcotic medications, attention deficit disorder medications